Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Products

Set Alert for Products

Generics Explore this Topic

Set Alert for Generics

Industry Pact Aligns Canadian Prices To International Levels

An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.

Canada Pricing Debate

Teligent Prepares For Injectables Filings With Strengthened Team

As it prepares to start injectables filings from its facility in Buena, New Jersey, Teligent is putting in place its senior operational and quality functions. 

United States Business Strategies

Sanders Maintains The Pressure On Teva, Mylan and Heritage

After urging the US DoJ to act against pharma companies alleged to have conspired in a price-fixing conspiracy, Bernie Sanders and Elijah Cummings write letters to Teva, Mylan and Heritage, accusing the companies of obstructing their enquiry.

Pricing Debate Pricing Strategies
See All

Biosimilars Explore this Topic

Set Alert for Biosimilars

German Medicines Safety Law Will ‘Do Nothing Against Shortages’

A provision in new German legislation that requires insurance funds to consider a variety of suppliers will do nothing to address drug shortages because it is not obligatory, local industry association Pro Generika believes.

Germany Legislation

Lupin Q1 Profit Up 50% But Regulatory Overhang, Slow Product Scale-Up Sparks Concern

Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Manufacturing Business Strategies

US Appeals Court Denies Genentech Injunction Over Amgen's 'At Risk' Trastuzumab Launch

Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.

Biosimilars Intellectual Property
See All

Value-Added Medicines Explore this Topic

Set Alert for Value-Added Medicines

Advanz Has Six Deals In The Works As It Cuts Its Losses

Advanz Pharma’s business development team is busty assessing potential deals as the recapitalized company works towards restoring profitability on an eroding revenues base.

M & A Deals

Pfenex And Alvogen May Face Delay In Teriparatide Equivalence Rating

Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.

Value-Added Medicines FDA

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.

Value-Added Medicines Deals
See All
UsernamePublicRestriction

Register